Irit Arbel Buys 2,500 Shares of Brainstorm Cell Therapeutics Inc. (BCLI) Stock
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Director Irit Arbel bought 2,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The stock was bought at an average cost of $4.26 per share, for a total transaction of $10,650.00. Following the completion of the acquisition, the director now owns 155,833 shares in the company, valued at approximately $663,848.58. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Brainstorm Cell Therapeutics Inc. (NASDAQ BCLI) traded down 0.47% during midday trading on Friday, hitting $4.24. The stock had a trading volume of 44,207 shares. The firm has a 50 day moving average price of $4.37 and a 200-day moving average price of $4.18. Brainstorm Cell Therapeutics Inc. has a 52-week low of $2.06 and a 52-week high of $5.18. The stock’s market cap is $79.56 million.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.06) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.04. Equities analysts predict that Brainstorm Cell Therapeutics Inc. will post ($0.58) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/irit-arbel-buys-2500-shares-of-brainstorm-cell-therapeutics-inc-bcli-stock/1538357.html.
A number of equities research analysts have commented on the company. Maxim Group set a $8.00 price target on Brainstorm Cell Therapeutics and gave the company a “buy” rating in a report on Saturday, July 22nd. ValuEngine raised Brainstorm Cell Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, July 22nd.
A number of hedge funds have recently added to or reduced their stakes in the stock. Sphera Funds Management LTD. purchased a new stake in shares of Brainstorm Cell Therapeutics during the second quarter worth about $2,759,000. Vanguard Group Inc. increased its stake in shares of Brainstorm Cell Therapeutics by 2.8% in the second quarter. Vanguard Group Inc. now owns 657,101 shares of the biotechnology company’s stock worth $2,733,000 after buying an additional 17,657 shares in the last quarter. Finally, KCG Holdings Inc. increased its stake in shares of Brainstorm Cell Therapeutics by 4.6% in the first quarter. KCG Holdings Inc. now owns 41,537 shares of the biotechnology company’s stock worth $177,000 after buying an additional 1,820 shares in the last quarter. Institutional investors own 12.74% of the company’s stock.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.
Receive News & Ratings for Brainstorm Cell Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.